Elkfork Partners’s Charles River Laboratories CRL Stock Holding History

Elkfork Partners’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$932K	Sell	7,040 -4,422	-39%	-$593K	0.02%	403
2019 Q2	$1.63M	Buy	11,462 +2,530	+28%	+$343K	0.04%	303
2019 Q1	$1.3M	Buy	8,932 +2,684	+43%	+$353K	0.03%	339
2018 Q4	$707K	Sell	6,248 -1,496	-19%	-$187K	0.02%	427
2018 Q3	$1.04M	Buy	7,744 +1,056	+16%	+$130K	0.02%	372
2018 Q2	$751K	Sell	6,688 -3,476	-34%	-$376K	0.02%	418
2018 Q1	$1.08M	Sell	10,164 -66	-0.6%	-$7.11K	0.03%	316
2017 Q4	$1.12M	Buy	10,230 +5,874	+135%	+$639K	0.03%	336
2017 Q3	$471K	Buy	4,356 +660	+18%	+$67.8K	0.01%	503
2017 Q2	$374K	Buy	3,696 +440	+14%	+$40.5K	0.01%	555
2017 Q1	$293K	Sell	3,256 -132	-4%	-$11.2K	0.01%	536
2016 Q4	$258K	Buy	+3,388	New	+$257K	0.01%	527

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Elkfork Partners's CRL Position: Q3 2019 in Review

Elkfork Partners reduced its Charles River Laboratories (CRL) stake by 39% in Q3 2019, selling an estimated $593K and leaving 7,040 shares worth $932K. The position accounts for 0.02% of the portfolio, ranked #403.

Elkfork Partners first reported a position in CRL in Q4 2016 and has held it in 12 quarters since. The position peaked at $1.63M in Q2 2019. 396 funds tracked by Wall St. Rank hold CRL as of Q3 2019.

Elkfork Partners held 7,040 shares of Charles River Laboratories worth $932K as of Q3 2019.
Elkfork Partners sold 4,422 Charles River Laboratories shares in Q3 2019, an estimated $593K.
Charles River Laboratories made up 0.02% of Elkfork Partners's portfolio in Q3 2019, its #403 holding.
Elkfork Partners first reported a position in Charles River Laboratories in Q4 2016 and has held it in 12 quarters since.
Elkfork Partners's Charles River Laboratories position peaked at $1.63M in Q2 2019.
396 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.